XaTek
The First Point-of-Care Diagnostic for Hemophilia & an Emerging Class of Anti-Coagulants

Trials

Clinical Investigation

XaTek has completed numerous successful feasibility studies on the ClotChip™ sensor.

Pilot Studies

1)          Phase I Clinical Trial

ClotChip™ Sensitivity in Target Specific oral Anticoagulants

The U.S. Department of Veterans Affairs, Cleveland, OH

September 2017 – July 2018

N=200

Results pending publication Fall 2018

 

2)          Phase I Clinical Trial

ClotChip™ Sensitivity in Hemophilia - In Vivo & Ex Vivo analyses

University Hospitals of Cleveland – Rainbow Babies & Children Hospital, Cleveland, OH

N=50

September 2018 anticipated start date

 

 

XaTek intends to conduct large multi-center Pivotal trials in both Hemophilia and the TSOAC class beginning in 2020